Abstract:New drugs to protect or mitigate total body irradiation (TBI) damage are urgently required. To determine whether existing pharmacologic agents have this second function, we used siRNA to screen 5,520 druggable targets in the Silencer Druggable Genome siRNA library (Version 1.1, Ambion, Austin, TX). We sought to identify genes which if silenced protected against or mitigated radiation damage. T98G human glioblastoma cells were transfected with each target in the siRNA library in triplicate at a final concentration of 20nM/target in a one-gene, one-well format using DharmaFECT2 transfection reagent and 48 hours later were irradiated to 25 Gy. Viability was measured 72 hours later using the CellTiter-Blue cell viability assay. The siRNA screen was performed three times and a hit was scored as a gene, which when silenced, protected T98G cells by at least 15% in each of the triplicate screens. We identified 117 candidate protective genes. These were further analyzed using Ingenuity Pathways Analysis to identify potential radiation inhibitor signaling pathways and drug candidates. One pharmacologically attractive candidate was glybenclamide. Glybenclamide is a sulfonylurea currently used to treat diabetes that inhibits the ATP-binding cassette, sub-family A (ABC1) and selectively blocks ATP sensitive potassium channels. Glybenclamide (10 μM) was added to 32D cl 3 murine hematopoietic progenitor cells one hour before irradiation, or immediately following irradiation. Cells were then irradiated to doses ranging from 0 to 8 Gy, plated in methylcellulose, and incubated for seven days at 37° C in a humidified CO2 incubator at which time colonies of greater than 50 cells were counted. The data were analyzed using linear quadratic or single-hit, multi-target models. Glybenclamide pre-irradiation treated cells were protected from irradiation as demonstrated by an increased shoulder on the survival curve with a n of 34.9 ± 0.5 compared to untreated 32D cl 3 cells or cells treated with glybenclamide after irradiation with a n of 3.1 ± 1.3 or 2.5 ± 0.9 (p = 0.0018 or < 0.0001, respectively). To determine if glybenclamide was radioprotective in vivo, we dissolved the drug in 50% Cremophor EL and 50% ethanol and then diluted 1:4 in water. C57BL/6NHsd female mice were injected intraperitoneally with 5 mg/kg glybenclamide either 10 minutes before or 10 minutes after TBI to the LD50/30 dose of 9.5 Gy. Duplicate groups received sucrose supplement to counteract potential hypoglycemia. We found that 60% of mice injected with glybenclamide before irradiation survived for 35 days compared to 33% for the TBI alone group (p = 0.0361), while 44% of mice injected with glybenclamide following irradiation survived. There was no significant effect of sucrose supplement or difference between irradiated controls, mice injected with vehicle only or glybenclamide following irradiation. These results demonstrate the power of unbiased siRNA screening with a druggable genome and suggest that glybenclamide might be a clinically useful radioprotector.

Glibenclamide, a Diabetic Drug, Prevents Acute Radiation-Induced Liver Injury of Mice Via Up-Regulating Intracellular ROS and Subsequently Activating Akt–NF-κB Pathway

Glibenclamide, A Diabetic Drug, Prevents Acute Radiation-Induced Liver Injury Of Mice Via Up-Regulating Intracellular Ros And Subsequently Activating Akt-Nf-Kappa B Pathway

KATP Channel Blocker Glibenclamide Prevents Radiation-Induced Lung Injury and Inhibits Radiation-Induced Apoptosis of Vascular Endothelial Cells by Increased Ca2+ Influx and Subsequent PKC Activation

Protective effect of the glucagon-like peptide-1 analogue liraglutide on carbon tetrachloride-induced acute liver injury in mice.

Druggable Genome Sirna-Screening Identifies Glybenclamide As A Radioprotector Against Total Body Irradiation

Low-dose radiation activates Akt and Nrf2 in the kidney of diabetic mice: a potential mechanism to prevent diabetic nephropathy.

Glycyrrhizin Ameliorates Radiation Enteritis in Mice Accompanied by the Regulation of the HMGB1/TLR4 Pathway

Sitagliptin Alleviates Radiation-Induced Intestinal Injury by Activating NRF2-Antioxidant Axis, Mitigating NLRP3 Inf--lammasome Activation, and Reversing Gut Microbiota Disorder

Inactivation of kupffer cells by gadolinium chloride protects murine liver from radiation-induced apoptosis.

Synthetic Protection Short Interfering RNA Screen Reveals Glyburide As a Novel Radioprotector

Transient Inhibition of Mtorc1 Signaling Ameliorates Irradiation-Induced Liver Damage

Enhanced autophagy protects hepatic cells from radiation injury

SGLT1 inhibition alleviates radiation-induced intestinal damage through promoting mitochondrial homeostasis

Methyl 6-O-cinnamoyl-α-d-glucopyranoside Ameliorates Acute Liver Injury by Inhibiting Oxidative Stress Through the Activation of Nrf2 Signaling Pathway

Gossypetin ameliorates ionizing radiation-induced oxidative stress in mice liver—a molecular approach

GLP‐1 receptor agonist liraglutide alleviates kidney injury by regulating nuclear translocation of NRF2 in diabetic nephropathy

GSK‐3β/Notch‐1 Activation Promotes Radiation‐Induced Renal Damage: The Role of Gallic Acid in Mitigation of Nephrotoxicity

Naringin alleviates gefitinib-induced hepatotoxicity through anti-oxidation, inhibition of apoptosis, and autophagy

Glibenclamide Ameliorates Transplant-Induced Arteriosclerosis and Inhibits Macrophage Migration and MCP-1 Expression.

Rosiglitazone Protects against Acetaminophen-Induced Acute Liver Injury by Inhibiting Multiple Endoplasmic Reticulum Stress Pathways

Rosiglitazone attenuates Acute Kidney Injury from hepatic ischemia-reperfusion in mice by inhibiting arachidonic acid metabolism through the PPAR-γ/NF-κB pathway